SEATTLE and VANCOUVER, BC,
Oct. 27, 2020 /PRNewswire/ --Achieve
Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical
company committed to the global development and commercialization
of cytisinicline for smoking cessation and nicotine addiction,
today announced the Company will host a Key Opinion Leader (KOL)
virtual roundtable event on cytisinicline and smoking cessation on
Tuesday, November 17th,
2020, at 12:00PM EST.
The event will include an overview by the principal investigator
of the ongoing ORCA-2 Phase 3 clinical trial of cytisinicline and
provide a review of the results from the RAUORA head-to-head study
of cytisinicline vs. Chantix® (varenicline). It will also
feature a panel discussion, moderated by healthcare analysts
Michael Higgins from Ladenburg
Thalmann and Thomas Flaten from Lake
Street Capital Markets, on the importance of smoking cessation in
the midst of the COVID-19 pandemic, with participation from the
following esteemed experts in the field of smoking cessation:
- Nancy Rigotti, MD - Professor of
Medicine, Harvard Medical School,
Director of Tobacco Research & Treatment, Massachusetts General Hospital, and ORCA-2
Principal Investigator
- Mitchell Nides, PhD - President, LA Clinical Trials LLC, ORCA-1
Principal Investigator
- Neal Benowitz, MD - Professor of
Medicine, Emeritus, University of California,
San Francisco
- Judith Prochaska, PhD, MPH -
Professor of Medicine, Stanford
University
- Scott Leischow, PhD - Professor
and Director, Clinical and Translational Science, Arizona State University, Former Senior Advisor for
Tobacco Policy at HHS
Additional details and registration information can be accessed
with this link or by visiting the Achieve website,
http://ir.achievelifesciences.com/events-and-webcasts.
About Achieve and Cytisinicline
Tobacco use is
currently the leading cause of preventable death that is
responsible for more than eight million deaths worldwide and nearly
half a million deaths in the U.S. annually.1,2 More than
87% of lung cancer deaths, 61% of all pulmonary disease deaths, and
32% of all deaths from coronary heart disease are attributable to
smoking and exposure to secondhand smoke.2
Achieve's focus is to address the global smoking health and
nicotine addiction epidemic through the development and
commercialization of cytisinicline.
Cytisinicline is a plant-based alkaloid with a high binding
affinity to the nicotinic acetylcholine receptor. It is believed to
aid in smoking cessation by interacting with nicotine receptors in
the brain by reducing the severity of nicotine withdrawal symptoms
and by reducing the reward and satisfaction associated with
smoking.
As an approved, branded product in Central and Eastern Europe for more than two decades, it
is estimated that over 20 million people have used cytisinicline to
help combat nicotine addiction.
Media
Contact
Glenn Silver
Glenn.Silver@Finnpartners.com
(646) 871-8485
Investor Relations Contact
Jason Wong
jwong@bplifescience.com
(415) 375-3340 ext. 4
Chantix® is a registered trademark of Pfizer
Inc.
References
1 World Health Organization. WHO Report on the Global
Tobacco Epidemic, 2019. Geneva:
World Health Organization, 2017.
2 U.S. Department of Health and Human Services. The
Health Consequences of Smoking – 50 Years of Progress. A Report of
the Surgeon General, 2014.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/achieve-life-sciences-to-host-smoking-cessation-key-opinion-leader-virtual-roundtable-on-november-17th-2020-301160210.html
SOURCE Achieve Life Sciences, Inc.